LONDON, 20 May 2008 - UK workers are more concerned about keeping their job than getting private treatment if they were diagnosed with cancer, according to research out today from Aon Consulting, a leading pensions, benefits and HR consultancy firm.

Around 1,300 working adults across the UK were asked what benefit they would prefer to receive if they were diagnosed with cancer. The findings showed that nearly one in two workers (49%) would opt for extended paid sick leave that would allow them to return to their job following treatment, in preference to funding for private treatment (27%), or a cash lump compensation payment with healthcare provided by the NHS (23%). This sentiment was reflected across the UK. The percentage of workers preferring to return to work through extended sick leave pay rose to nearly 60% amongst workers in Leeds but dipped slightly to 43% of Manchester workers.

The results showed that among male and female workers, female workers are much more likely than their male colleagues to opt for extended sick leave pay (58% vs. 41%). Indeed, nearly a third of men favoured funding of private treatment compared with just under a quarter of women (23%).

Interestingly, the findings demonstrate that workers are prepared to put their faith in NHS cancer treatment despite findings in 2006 from the government’s National Radiotherapy Advisory Group that showed British cancer patients get 25% less treatment than their European counterparts. Currently over 90,000* of the UK workforce are diagnosed with cancer each year and the number is expected to rise significantly putting further pressure on the NHS and calling into question its ability to fund treatment. There are fears from leading cancer specialists that NHS patients risk losing out on revolutionary cancer treatment that they are currently unable to pay towards.

For UK employers, the findings clearly show the need to review current policies and benefits to ensure they are not funding expensive treatments that their employees may not value. Currently employers appear happy to offer funding for costly treatments to those covered under private care at the expense of alternatively investing in improved rehabilitation and support for all.

The findings are also interesting for employers in terms of the pressure on healthcare benefit plans. At the moment in the UK the default position is to fund all NICE (National Institute for Clinical Excellence) approved drugs and/or to extend this to include any drug satisfying the European Medicines Agency license criteria. The main providers are already estimating that this is set to add at least 5% to already high medical inflation (10%). If it remains unchecked, the reality is that the effect might be much higher.

Commenting on the findings, Alex Bennett, head of healthcare at Aon Consulting said: "It is interesting for employers to note that most workers value the security of maintaining their income and one day returning to work over alternatives of lump sum compensation or access to private healthcare. Of course, it is unclear how much this view might change if the NHS proves unable to provide groundbreaking drug therapies.

"The findings show a real need for employers to assess whether current policies and benefits match up with what their employees really need. Reconfiguring these to provide employees with choices, and their colleagues with support to welcome them back, may make more sense than funding expensive treatments that may not be as valued as the alternatives."

Ends

*Source: Cancer Research

For more information contact
Leo Wood / Susie Patterson
0207 269 7137 / 233
leo.wood@fd.com  / susie.patterson@fd.com
http://aon.mediaroom.com 

About Aon Consulting
Aon Consulting is a leading human capital consultancy, helping organisations of every size to attract and keep the employees they need. We advise on all aspects of employment, including health-related insurance and risk; employee compensation and pensions; human resource strategy planning; job design and change management; and staff assessment and legal issues. Aon Consulting is a division of Aon, one of the UK's largest insurance brokers and providers of risk management services and a major force in reinsurance and the UK human capital consulting market. Aon Consulting Limited is authorised and regulated by the Financial Services Authority.

About Aon
Aon Corporation (NYSE:AOC) is the leading global provider of risk management services, insurance and reinsurance brokerage, human capital and management consulting. Through its 36,000 colleagues worldwide, Aon readily delivers distinctive client value via innovative and effective risk management and workforce productivity solutions. Our industry-leading global resources, technical expertise and industry knowledge are delivered locally through more than 500 offices in more than 120 countries. Aon was named the world's "best broker" by Euromoney magazine's 2008 Insurance Survey. Aon also was ranked by A.M. Best as the number one global insurance brokerage in 2007 based on brokerage revenues, and voted best insurance intermediary, best reinsurance intermediary, and best employee benefits consulting firm in 2007 by the readers of Business Insurance. For more information on Aon, log onto aon.mediaroom.com.

This press release contains certain statements related to future results, or states our intentions, beliefs and expectations or predictions for the future which are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety of factors. Potential factors that could impact results include: general economic conditions in different countries in which we do business around the world, changes in global equity and fixed income markets that could affect the return on invested assets, fluctuations in exchange and interest rates that could influence revenue and expense, rating agency actions that could affect our ability to borrow funds, funding of our various pension plans, changes in the competitive environment, our ability to implement restructuring initiatives and other initiatives intended to yield cost savings, changes in commercial property and casualty markets and commercial premium rates that could impact revenues, the outcome of inquiries from regulators and investigations related to compliance with the U.S. Foreign Corrupt Practices Act and non-U.S. anti-corruption laws, the impact of investigations brought by U.S. state attorneys general, U.S. state insurance regulators, U.S. federal prosecutors, U.S. federal regulators, and regulatory authorities in the U.K. and other countries, the impact of class actions and individual lawsuits including client class actions, securities class actions, derivative actions, ERISA class actions, and the cost of resolution of other contingent liabilities and loss contingencies. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, is contained in the Company's filings with the Securities and Exchange Commission.

Aon Limited is authorised and regulated by the Financial Services Authority in respect of insurance mediation activities only.